Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase I

McMaster University

$146,850.00

A novel dopamine D2 receptor allosteric modulator: Development and commercialization of a safer more effective generation of antipsychotic drugs

FY 2010-11

Summary
Dopamine is a chemical found in the central nervous system and is known to regulate mood, attention, and other important brain functions. Several mental disorders such as schizophrenia involve dysregulation of dopamine signaling. This disease affects over 1% of the global population, and have a yearly economic burden of approximately $35 billion in the United States alone. Current treatments are largely inadequate for several reasons and often rely on targeting the dopamine D2 receptor with varying success. As traditional treatment methodologies involve blocking or activating the dopamine D2 receptor by binding to the same site as dopamine, they cause an array of adverse effects. For example, antipsychotics used for the treatment of schizophrenia block the dopamine D2 receptor and are only effective in alleviating some of the symptoms. Additionally, these therapeutics can result in weight gain, diabetes, and various movement disorders. Evidently, there is a strong demand for a new generation of pharmaceuticals to treat mental disorders while avoiding the adverse effects of current therapeutics. Our lab has developed a new compound, PAOPA, for the treatment of schizophrenia and neurological disorders related to the dopamine D2 receptor. Uniquely, this drug works by binding to an alternative site on the D2 receptor, adjusting dopamine activity n a safer, more effective way. Past studies have shown that PAOPA increases response of dopamine receptors in the brain to dopamine. PAOPA has also been shown to be effective in the treatment and prevention of schizophrenic-like symptoms in animal models, with no side effects. In addition, when administered with traditional antipsychotics, PAOPA prevents the unwanted development of movement and metabolic disorders. With this funding, PAOPA can be developed into a new, highly effective class of antipsychotics with minimal side effects.
Program
Proof of Principle Program - Phase I
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
227906
Name
Mishra Ram K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
A novel dopamine D2 receptor allosteric modulator: Development and commercialization of a safer more effective generation of antipsychotic drugs
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$146,850
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Allosteric Modulators; Antipsychotics; Cns Disorders; Dopamine; Dopamine D2 Receptors; G-Protein Coupled Receptors; Parkinson'S Disease; Prodromal Treatment; Schizophrenia
Abstract
Dopamine is a chemical found in the central nervous system and is known to regulate mood, attention, and other important brain functions. Several mental disorders such as schizophrenia involve dysregulation of dopamine signaling. This disease affects over 1% of the global population, and have a yearly economic burden of approximately $35 billion in the United States alone. Current treatments are largely inadequate for several reasons and often rely on targeting the dopamine D2 receptor with varying success. As traditional treatment methodologies involve blocking or activating the dopamine D2 receptor by binding to the same site as dopamine, they cause an array of adverse effects. For example, antipsychotics used for the treatment of schizophrenia block the dopamine D2 receptor and are only effective in alleviating some of the symptoms. Additionally, these therapeutics can result in weight gain, diabetes, and various movement disorders. Evidently, there is a strong demand for a new generation of pharmaceuticals to treat mental disorders while avoiding the adverse effects of current therapeutics. Our lab has developed a new compound, PAOPA, for the treatment of schizophrenia and neurological disorders related to the dopamine D2 receptor. Uniquely, this drug works by binding to an alternative site on the D2 receptor, adjusting dopamine activity n a safer, more effective way. Past studies have shown that PAOPA increases response of dopamine receptors in the brain to dopamine. PAOPA has also been shown to be effective in the treatment and prevention of schizophrenic-like symptoms in animal models, with no side effects. In addition, when administered with traditional antipsychotics, PAOPA prevents the unwanted development of movement and metabolic disorders. With this funding, PAOPA can be developed into a new, highly effective class of antipsychotics with minimal side effects.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mishra, Ram K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $146,850~ $0~
McMaster University - $146,850 Grant (2010-11) | Canada Spends